© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
COVID-19 2024-2025 Vaccines 33% Effective Against Hospitalization, ED Visits in Adults: Early Data
March 04, 2025
CDC midseason data suggest low COVID-19 vaccine efficacy in adults aged 18 to 64 years, with somewhat better impact on those aged 65 years and older.
What to Know Before AAD 2025: Product Snapshots of Nonsteroidal Topical Treatments for Eczema
March 04, 2025
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
WHO Recommends Flu Vaccine Composition for 2025-26 Northern Hemisphere Season as US HHS Cancels ACIP, VRBAC Meetings
March 03, 2025
Two official US vaccine planning meetings cancelled in February is an "unprecedented situation," said NFID medical director Robert Hopkins, Jr, MD.
sNDA for Roflumilast Cream 0.05% for the Treatment of AD in Children Aged 2 to 5 Years Gets FDA Nod
March 03, 2025
The FDA has set a PDUFA target action date for October 13, 2025, according to Arcutis Biotherapeutics.
Omalizumab Efficacy and Safety Shown Superior to OIT in First Head-to-Head Multi-Food Allergy Trial
March 03, 2025
Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.
Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy
March 03, 2025
The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Pediatric Anaphylaxis Study
March 03, 2025
Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.
Atopic Dermatitis Primer for AAD 2025: Dermatologist Mona Shahriari, MD, Explains the Rise in Prevalence
March 03, 2025
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
Dupilumab Reduces Specific IgE to Foods at 12 and 24 Months in Small Study
February 28, 2025
AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.
Perimenopause Symptoms May Affect More Than Half of Women as Young as Age 30
February 28, 2025
Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.